Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия e.a.butorova@mail.ru
Список исп. литературыСкрыть список 1. Merlini G, Westermark P. The systemic: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004; 255: 159–78. 2. Wechalekar AD, Gillmore JD, Hawkins PN. Systemicamyloidosis. Lancet 2016; 387 (10038): 2641–54. 3. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart 2012; 98: 1546–54. 4. Rapezzi C, Quarta CC, Riva L et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010; 7: 398–408. 5. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000; 45: 107–37. 6. Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration: analysis of four years’ experience. Am J Med. 1987; 82: 412–4. 7. Garcia-Pavia P, Comin-Colet J, Barriales-Villa R et al. Comments on the 2014 ESC Guidelines on the diagnosis and management of hypertrophic cardiomyopathy. A critical view from the perspective of Spanish cardiology. Rev Esp Cardiol 2015; 68: 4–9. 8. Mavrogeni SI, Vartela V, Ntalianis A et al. Cardiac amyloidosis: in search of the ideal diagnostic tool. Herz 2019. 9. González-López E, Gallego-Delgado M, Guzzo-Merello G et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36 (38): 2585–94. 10. Gillmore JD, Maurer MS, Falk RH et al. Nonbiopsydiagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404–12. 11. Ruberg FL, Appelbaum E, Davidoff R et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Amer J Cardiol 2009; 103 (4): 544–9. 12. White SK, Sado DM, Flett AS, Moon J. Characterising the myocardial interstitial space: the clinical relevance non-invasive imaging. Heart 2012; 98: 773–9. 13. Aquaro GD, Pugliese NR, Perfetto F et al. Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis. Int J Cardiovasc Imaging 2014; 30 (6): 1105–15. 14. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3: 155–64. 15. Стукалова О.В. Магнитно-резонансная томография сердца с отсроченным контрастированием – новый метод диагностики заболеваний сердца. Российский электронный журнал лучевой диагностики. 2013; 3: 7–18. [Stukalova OV. Magnetic resonance imaging of the heart with delayed contrast is a new method for diagnosing heart diseas-es. Russian Electronic Journal of Radiation Diagnostics. 2013; 3: 7–18 (in Russian)]. 16. Sipe JD, Benson MD, Buxbaum JN et al; Nomenclature Committee of the International Society of Amyloidosis. Amyloid fi bril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012; 19: 167–70. 17. Chatzantonis G, Bietenbeck M, Elsanhoury A et al. Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol 2020. DOI: 10.1007/s00392-020-01771-1 18. Vogelsberg H, Mahrholdt H, Deluigi CC et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51: 1022–30. 19. Ana Martinez-Naharro, Thomas A. Treibel, Amna Abdel-Gadir et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol 2017; 70 (4): 466–77. 20. Fontana M, Banypersad SM, Treibel TA et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and lightchain amyloidosis: a cardiac MR imaging study. Radiology 2015; 277: 388–97.